Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

2021269 citationsJournal Articlehybrid Open Access

Authors

Dennis J. Slamon · University of California, Los Angeles

Patrick Neven · Universitair Ziekenhuis Leuven

Stephen Chia · BC Cancer Agency

Guy Jérusalem · University of Liège

Michelino De Laurentiis · Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Sin‐Hyeog Im · Seoul National University Hospital

Katarína Petráková

Abstract

This analysis reported extended OS follow-up in MONALEESA-3. mOS was ∼12 months longer in patients with HR+/HER2- ABC treated with ribociclib plus fulvestrant compared with fulvestrant monotherapy.

Topics & Keywords

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Oncology

Volume 32, Issue 8, pp. 1015-1024

DOI: 10.1016/j.annonc.2021.05.353

Field-Weighted Citation Impact: 31.31